Insider Selling: Paysign, Inc. (NASDAQ:PAYS) CEO Sells 61,000 Shares of Stock

Paysign, Inc. (NASDAQ:PAYS) CEO Mark Newcomer sold 61,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $2.89, for a total transaction of $176,290.00. Following the completion of the transaction, the chief executive officer now owns 9,075,886 shares in the company, valued at $26,229,310.54. This represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mark Newcomer also recently made the following trade(s):

• On Thursday, January 23rd, Mark Newcomer sold 12,000 shares of Paysign stock. The shares were sold at an average price of $2.85, for a total transaction of $34,200.00.
• On Monday, December 9th, Mark Newcomer sold 41,000 shares of Paysign stock. The shares were sold at an average price of $3.31, for a total transaction of $135,710.00.
• On Wednesday, November 20th, Mark Newcomer sold 25,000 shares of Paysign stock. The stock was sold at an average price of $3.27, for a total value of $81,750.00.
• On Monday, November 18th, Mark Newcomer sold 40,000 shares of Paysign stock. The shares were sold at an average price of $3.24, for a total value of $129,600.00.

Paysign Trading Down 1.0 %

Paysign stock opened at $2.87 on Friday. The stock has a market capitalization of $153.68 million, a price-to-earnings ratio of 19.13 and a beta of 0.95. The stock has a 50 day moving average of $3.13 and a two-hundred day moving average of $3.89. Paysign, Inc. has a twelve month low of $2.70 and a twelve month high of $5.59.

Paysign (NASDAQ:PAYS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. The firm had revenue of $15.26 million for the quarter, compared to analyst estimates of $14.96 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. During the same period last year, the firm posted $0.02 EPS. Equities analysts predict that Paysign, Inc. will post 0.21 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Barrington Research reaffirmed an “outperform” rating and set a $7.00 price target on shares of Paysign in a research report on Monday, November 4th. Lake Street Capital started coverage on shares of Paysign in a research report on Friday, December 20th. They issued a “buy” rating and a $6.00 price target for the company.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in Paysign by 25.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock worth $6,484,000 after purchasing an additional 301,000 shares during the period. Royce & Associates LP acquired a new position in Paysign during the third quarter worth $814,000. Barclays PLC raised its position in Paysign by 327.4% in the third quarter. Barclays PLC now owns 47,090 shares of the company’s stock worth $173,000 after acquiring an additional 36,071 shares in the last quarter. Rhumbline Advisers lifted its holdings in Paysign by 25.1% in the second quarter. Rhumbline Advisers now owns 35,835 shares of the company’s stock valued at $154,000 after acquiring an additional 7,190 shares during the period. Finally, Joule Financial LLC purchased a new stake in shares of Paysign during the 3rd quarter worth $1,478,000. 25.89% of the stock is owned by hedge funds and other institutional investors.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.